Hypochondroplasia Diagnosis

Hypochondroplasia is a rare genetic skeletal dysplasia caused by pathogenic variants in the fibroblast growth factor receptor 3 gene. According to the source, approximately 1 in 15,000 to 1 in 75,000 live births are affected by hypochondroplasia.

Introduction to Hypochondroplasia

The condition is characterized by disproportionate short stature and relative macrocephaly. Estimates of prevalence range from approximately 1 in 15,000 to 1 in 75,000 live births, but the true frequency is probably higher because milder cases might be undiagnosed. Severe hypochondroplasia can phenotypically overlap with the allelic condition achondroplasia, but skeletal features tend to be more subtle in hypochondroplasia.

Diagnostic Challenges

Diagnostic uncertainty remains common, particularly in early childhood and in individuals with mild or atypical presentations, leading to delayed diagnosis, inconsistent management, and challenges in counselling and care planning. The effect of hypochondroplasia on individuals extends beyond reduced stature, and complications can include orthopaedic issues, ear, nose and throat, and respiratory complications, as well as neurodevelopmental and neurological complications.

Developing Diagnostic Recommendations

To address these challenges, an international, multidisciplinary panel of experts and patient representatives convened to develop consensus-based diagnostic recommendations using a modified two-stage Delphi approach. The panel integrated clinical, anthropometric, radiographic, neuroimaging, and genetic criteria to define diagnostic categories that can be applied across diverse health-care settings globally. Major and minor diagnostic criteria are proposed, alongside guidance on the appropriate use of molecular testing, radiographic evaluation, and brain magnetic resonance imaging.

The International Achondroplasia Forum (IAF) used a modified Delphi process to consolidate their insights and expertise, alongside those of other experts in hypochondroplasia, into a set of diagnostic recommendations. A core group of five hypochondroplasia experts was established to lead the Delphi process, and experts from the IAF steering committee, additional experts with specific clinical, molecular, and/or global expertise in hypochondroplasia, and patient representatives were approached to be part of the insight-gathering group and subsequent Delphi panel. The outcomes of that Delphi process are reported in the source, which includes a literature search on PubMed using the search term ‘hypochondroplasia’ and the development of a set of diagnostic recommendations that integrate clinical, radiographic, and genetic approaches.

Early and accurate diagnosis of hypochondroplasia offers opportunities for monitoring and intervention, and for the timely delivery of developmental support and genetic counselling. Several growth-modifying therapies are undergoing clinical evaluation in patients with hypochondroplasia, and if approved for use, these therapies have the potential to improve growth and reduce skeletal complications in individuals with hypochondroplasia. The source highlights the need for diagnostic recommendations that integrate clinical, radiographic, and genetic approaches to improve recognition and facilitate earlier diagnosis in individuals with hypochondroplasia, and to support optimal care, which could in future include precision treatments currently in development.